JNJ-78934804 Shows Efficacy in Crohn's Disease Compared to Guselkumab
A study is underway to evaluate the efficacy and safety of JNJ-78934804 against guselkumab in Crohn's disease patients at Week 48.
Company
Pharmaceutical intelligence for JNJ-78934804 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.